Post Authorisation Safety Study With Raxone in LHON Patients — PAROS

Leber's Hereditary Optic Neuropathy (LHON) Clinical Trial

Official title:
A Non-interventional Study of Clinical Experience in Patients Prescribed Raxone® for the Treatment of Leber's Hereditary Optic Neuropathy (LHON)

Status Completed

Clinical Trial Summary

This study is a multicentre, prospective, non-interventional post-authorisation safety study (PASS) of the clinical outcomes for patients with LHON treated with Raxone®. No medication will be provided as part of this study. Raxone® will be obtained through commercial channels.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Leber's Hereditary Optic Neuropathy (LHON)
Optic Atrophy, Hereditary, Leber
Optic Nerve Diseases

Clinical Trial Details

NCT number	NCT02771379
Study type	Observational
Source	Santhera Pharmaceuticals
Contact
Status	Completed
Phase
Start date	September 2016
Completion date	April 16, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02774005` - Study to Assess the Efficacy and Safety of Raxone in LHON Patients	Phase 4
Completed	`NCT02796274` - Historical Case Record Survey of Visual Acuity Data From Patients With Leber's Hereditary Optic Neuropathy (LHON)
Recruiting	`NCT04912843` - Gene Therapy Clinical Trial for the Treatment Of Leber's HereDitary Optic Neuropathy	Phase 2/Phase 3
Terminated	`NCT01389817` - Near-infrared Light-emitting Diode (NIR-LED) Therapy for Leber's Hereditary Optic Neuropathy (LHON)	Phase 1/Phase 2
Completed	`NCT05555784` - Evaluation of Impact of Disease and Visual Disability on Quality of Life and Loss of Independence of Patients Living in France With Leber's Hereditary Optic Neuropathy (LHON) Through Qualitative and Quantitative Data Collection